Dyne Therapeutics, Inc. — Q2 2023 Form 10-Q
Reporting period: Quarter and six months ended June 30, 2023. Dyne is a clinical-stage biotechnology company developing muscle-disease therapeutics using its FORCE platform. It had no product revenue and no approved products.
Financial performance and position
| Metric | Q2 2023 | Q2 2022 | Six months 2023 | Six months 2022 |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Research and development expense | $59.1 million | $46.7 million | $96.7 million | $74.9 million |
| General and administrative expense | $7.6 million | $6.1 million | $15.5 million | $13.6 million |
| Total operating expenses | $66.7 million | $52.8 million | $112.2 million | $88.5 million |
| Net loss | $64.9 million | $52.3 million | $109.1 million | $87.9 million |
| Basic and diluted loss per share | $1.08 | $1.01 | $1.88 | $1.70 |
| Operating cash used | Not separately stated | Not separately stated | $102.6 million | $81.6 million |
At June 30, cash and cash equivalents were $167.6 million and marketable securities were $40.1 million, totaling $207.7 million; restricted cash was an additional $2.3 million. Total assets were $251.4 million, current liabilities $20.2 million, total liabilities $44.5 million, and accumulated deficit $505.7 million. Reported liabilities were primarily leases; lease liabilities totaled $29.0 million. The filing reports no debt financing outstanding.
For the six months, investing activities provided $44.3 million, largely from maturities of marketable securities; financing activities provided $53.7 million, including $52.4 million of net ATM offering proceeds. Cash, cash equivalents and restricted cash declined $4.5 million to $169.9 million. Profit margins are not meaningful because the company had no revenue and incurred operating losses.
Changes versus the prior comparable period
- Q2 operating expenses increased $14.0 million year over year, and net loss widened by $12.6 million. For the first half, operating expenses rose $23.7 million and net loss widened by $21.2 million.
- Q2 R&D expense rose $12.5 million. DYNE-101 costs increased with clinical-trial activity and manufacturing supply; DYNE-251 costs decreased in the quarter due mainly to timing of manufacturing costs, partly offset by increased trial activity. First-half R&D costs increased for both programs.
- Higher interest income partly offset operating losses: $2.2 million in Q2 2023 versus $0.4 million in Q2 2022, reflecting returns on invested cash.
- Cash and marketable securities were $207.7 million at June 30, down from $256.0 million at December 31, 2022. The company raised $52.4 million net through its at-the-market program during the first half, issuing 4.51 million shares.
Outlook, programs and risks
- Management stated that existing cash, cash equivalents and marketable securities were expected to fund operating expenses and capital requirements through 2024 and to support proof-of-concept data readouts for DYNE-101 and DYNE-251. The filing cautions that this estimate relies on assumptions and funding could be exhausted sooner. The financial-statement note separately says resources are expected to cover at least 12 months from issuance.
- DYNE-101 is in the Phase 1/2 ACHIEVE trial for myotonic dystrophy type 1 (DM1); DYNE-251 is in the Phase 1/2 DELIVER trial for eligible Duchenne muscular dystrophy (DMD) patients. Management anticipated initial safety, tolerability and biomarker data from both trials in the second half of 2023.
- DYNE-301 for facioscapulohumeral muscular dystrophy (FSHD) was deferred as the company prioritized DYNE-101 and DYNE-251; management planned an FSHD program update by year-end 2023. The EMA granted orphan-drug designation to DYNE-101 in May 2023; the FDA granted orphan-drug and rare-pediatric designations to DYNE-251 in March 2023. DYNE-251 had received FDA Fast Track designation in October 2022.
- The company expects significant and increasing R&D spending and operating losses, and will need substantial additional funding. Potential financing may dilute shareholders or require restrictive terms or rights concessions. No committed external source of capital was disclosed.
- Key risks include clinical and regulatory failure or delay, limited rare-disease patient pools, unproven platform technology, reliance on third-party and single-source manufacturers, competition, intellectual-property challenges, and future financing needs. The company also highlighted uninsured-deposit exposure and uncertainty around future reimbursement and drug pricing.
- No legal proceedings were reported. Management concluded disclosure controls were effective at the reasonable-assurance level; no material change in internal control over financial reporting was reported for the quarter.
Important facts for investors to verify
- Whether anticipated DYNE-101 and DYNE-251 clinical readouts occurred on schedule and what the full safety, tolerability and efficacy-related data showed.
- Whether the stated cash runway through 2024 remains achievable given operating cash use of $102.6 million in the first half and planned clinical and manufacturing spending.
- Future financing needs, remaining ATM capacity and the potential dilution from additional share issuance; shares outstanding were 61.0 million at June 30.
- Progress and supply continuity for the clinical programs, including dependence on third-party manufacturers and single-source components.
- Timing and scope of any update to the deferred DYNE-301/FSHD program and implications for resource allocation.